The Department of Defense, through its Tuberous Sclerosis Complex Research Program (TSCRP), is offering this Clinical Trial Award. Established in 2002, the TSCRP’s mission is to foster innovative research that aims to decrease the clinical impact of Tuberous Sclerosis Complex (TSC) by understanding its pathogenesis and translating discoveries into improved patient care. This grant specifically supports clinical trials, which involve the prospective accrual of human subjects to test interventions like drugs, devices, or procedures. The goal is to measure outcomes related to exploratory information, safety, effectiveness, and/or efficacy, ensuring a direct impact on the human subject. Preclinical research is not eligible for this funding.
Opportunity ID: 91273
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-11-TSCRP-CTA |
| Funding Opportunity Title: | DOD FY11 Tuberous Sclerosis Complex Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 03, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 04, 2011 |
| Current Closing Date for Applications: | Aug 04, 2011 |
| Archive Date: | Sep 03, 2011 |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Tuberous Sclerosis Complex Research Program (TSCRP) was established in 2002 to promote innovative research focused on decreasing the clinical impact of tuberous sclerosis complex (TSC). The mission of the TSCRP is to encourage innovative research aimed at understanding the pathogenesis of TSC, and to translate these findings to the care of individuals with TSC. The TSCRP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of TSC. Funding from this award mechanism must support a clinical trial and cannot be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP and eReceipt HELP: 301-682-5507
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 91273 Full Announcement-1 -> tscrp_fy11 cta pa_gg.pdf
Packages
| Agency Contact Information: | PA HELP and eReceipt HELP: 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00051410 | May 03, 2011 | Aug 04, 2011 | View |
Package 1
Mandatory forms
91273 RR_SF424_1_2-1.2.pdf
91273 PerformanceSite_1_4-1.4.pdf
91273 RR_Budget-1.1.pdf
91273 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
91273 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
